260976-37-2

Upstream product

• 851895-41-5 p-methylphenyl 2,3,6-tri-O-benzyl-1-deoxy-1-thio-β-D-glucopyranoside 
• 100-39-0 benzyl bromide 

Downstream Products

• 260976-38-3 2-(trimethylsilyl)ethyl (4-azido-2,3,6-tri-O-benzyl-4-deoxy-α-D-galactopyranosyl)-(1->4)-2,3,6-tri-O-benzoyl-β-D-galactopyranoside 

Relevant academic research and scientific papers

Efforts toward rational design of Th2-bias immune stimulator through modification on D-Gal-C-4 of α-GalCer derivative

α-Galactosylceramide (α-GalCer) initiates immune response by activating iNKT cells in a CD1d restricted way. However, its clinical application is quite limited mainly because of the simultaneous secretion of antagonizing Th1- and Th2-type cytokines. With the help of molecular computation, we conducted a rational design of glycolipid to expect a Th2-bias immune response. Accordingly, some of the designed D-galactopyranosyl lipids were synthesized, and their abilities to induce Th2 cytokines through stimulating iNKT cells were investigated both in vitro and in vivo. We found that modification on Gal-C-4 of glycolipids could possibly increase Th2-selecivity, although the cytokine productivity was suppressed ascribing to the weaken interaction of CD1d and TCR in CD1d/glycolipid/TCR triplex.

Synthesis of selected aminodeoxy analogues of galabiose and globotriose

Six aminodeoxy 2-(trimethylsilyl)ethyl (Me3SiEt) glycoside analogues of galabiose (4'- and 6'-aminodeoxy) and globotriose (6''-, 4''-, 2''-, and 6'-aminodeoxy) were synthesized by glycosylation of protected Me3SiEt galactoside and lactoside acceptors with azido-substituted monosaccharide donors, followed by reduction of the azido groups and removal of the protecting groups. Copyright (C) 1999 Elsevier Science Ltd.